Quick Take
Foreigners are increasingly flying to China for cancer treatment — and the numbers now back up a trend this site has tracked for years. According to the National Health Commission's 2025 cross-border medical services report, China's key international hospitals received 1.28 million international patient visits for the year, up 73.6% from three years earlier, while cross-border medical revenue exceeded ¥80 billion in the first three quarters alone, growing more than 30% a year. The drivers are concrete: therapies approved only in China, prices that can run to a third of US levels, and wait times measured in days rather than months. Two patient cases — a New Zealand man's ¥990,000 (≈US$140,000) CAR-T shot and an American's last-line immunotherapy — illustrate what the trend actually looks like on the ground.
1. The Trend in Numbers
The clearest signal that "medical tourism to China" has moved from niche to mainstream is in the government's own data:
| Metric | Figure | Source |
|---|---|---|
| International patient visits (2025) | 1.28 million | NHC 2025 report |
| Growth vs three years earlier | +73.6% | NHC 2025 report |
| Cross-border medical revenue (Q1–Q3) | > ¥80 billion | NHC 2025 report |
| Annual revenue growth | > 30% | NHC 2025 report |
| Western patients | doubled | NHC 2025 report |
| New international wards announced (Q1 2026) | 9 hospitals | Caijing |
The fastest-growing categories are the ones tied to survival: oncology, cardiovascular surgery, and CAR-T cell immunotherapy. That is not an accident — patients cross borders when local options run out.
2. Two Patients, Two Different Reasons
The Caijing report follows two patients whose cases capture both halves of the trend.
Josh, 59, New Zealand — access to a therapy that exists nowhere else. After standard chemotherapy and immunotherapy failed in New Zealand, Josh was too weak to eat and was surviving on enteral nutrition. He researched cutting-edge oncology treatments online and found satri-cel — the world's first CAR-T approved for a solid tumor, cleared in China in June 2026 for CLDN18.2-positive gastric cancer. In August 2026, after roughly six weeks of treatment at Jiahui International Hospital in Shanghai, he hugged his lead doctor and flew home alone on an 11.5-hour flight. One infusion cost ¥990,000. We covered Josh's case in detail here.
Daniel, an American — one last option the US system could not offer. After four lines of treatment that kept failing, his doctors at MD Anderson Cancer Center told him they had nothing left to try — but flagged that ivonescimab (依沃西), a China-developed bispecific immunotherapy, might be his last hope and was only approved in China. His children, both physicians, arranged his care. He arrived in Shanghai in March 2026. When he developed a serious immune-related adverse reaction during treatment and was moved to intensive care, Jiahui convened multiple rounds of multidisciplinary consultation and brought in the drug's principal investigator, Prof. Caicun Zhou of Shanghai East Hospital, to help manage it. We covered the ivonescimab data here.
Two men, two diseases, two different products — one pattern: China was the only place the treatment existed.
3. The Cost Gap
Price is the second reason, after access. Jiahui's written response to Caijing puts it plainly: blood-cancer CAR-T in China costs about one-third of the US price. A single solid-tumor CAR-T infusion was reported at ¥990,000 (≈US$140,000) — expensive in absolute terms, but a fraction of what the same class of therapy lists for in the United States, where approved BCMA and CD19 products run from roughly $400,000 to over $500,000 before hospital and drug costs.
It is worth keeping the scale honest. Even at a third of US prices, ¥990,000 is a serious amount — in New Zealand, where Josh is from, the average annual salary is about ¥356,000. Most patients who travel to China pay out of pocket, often after exhausting treatment and insurance options at home. The point is not that China is cheap; it is that for therapies that are either unavailable or unaffordable elsewhere, China is the accessible option.
Full cost picture: beyond the therapy itself, international patients pay for travel, accommodation, interpretation, and post-treatment follow-up. Our CAR-T cost guide breaks down the complete budget.
4. Why China, Beyond Price: Speed and Volume
Two structural advantages keep coming up in hospital interviews, and neither is about cost.
Speed. Jiahui reports completing a full oncology and hematology workup — bone marrow aspiration, laboratory tests, PET-CT, cardiac ultrasound, and pulmonary function — with results and a doctor discussion within 48 hours. In China, the gap from first cancer diagnosis to surgery typically runs one to two weeks, versus months in many Western systems, where even a PET-CT can take days to schedule and requires insurance pre-authorization.
Surgical volume. Dr. Yongbing Zhou, vice president of Peking University International Hospital, makes the case bluntly: a Chinese thoracic surgeon performs 400–500 surgeries a year, sometimes over 1,000, while a Western counterpart might perform around 100. Both technical skill and exposure to complex cases, he argues, favor the Chinese physician.
For a patient deciding where to get a complex procedure, those two factors — how soon, and how many times the surgeon has done it — often outweigh a lower price tag.
5. How the International Wards Actually Work
The infrastructure behind the trend is growing fast. A few things patients should understand:
- International departments are the entry point. Under national policy, public hospitals may run international (premium) services up to 10% of total volume. In January–February 2026 alone, at least seven hospitals announced new international wards, and Guangdong named its first 25 international-care pilot hospitals in March.
- Pricing is higher, and tiered. International wards are private-pay, not public insurance. Registration fees at one Beijing children's hospital's international ward run ¥1,000–1,500, versus ¥50–100 in the regular clinic; overall, international-ward prices are roughly 3–10× the public-insurance benchmark, with surgical fees at the high end.
- Language is handled. Jiahui provides care in eight languages and medical records in more than 20; Peking University International Hospital collects patient history before the visit through a dedicated line. English accompaniment is standard at the well-run centers.
- Payment is mostly self-pay for foreign patients. Even patients with international insurance usually pay first and claim reimbursement after returning home, though hospitals are working to connect directly with international insurers. Peking University International Hospital already partners with 45 commercial insurers.
For a first-timer, the practical message is: international wards are designed for exactly this — a foreigner arriving without Chinese language, a local insurance card, or familiarity with the system.
6. What This Does Not Mean
Three honest caveats, because the trend invites overstatement:
- "Cheap" is relative. CAR-T at a third of US prices is still a five-figure-plus decision, mostly paid out of pocket. Budget the full trip, not just the drug.
- Not every treatment is a success. Josh's case is a single patient; Daniel needed intensive care for an immune reaction. Frontier therapy carries real risk, and outcomes vary.
- China is not the answer for everyone. Many conditions are well-treated at home. China makes the most sense when a therapy is only approved here, when wait times at home are dangerously long, or when cost rules out the equivalent treatment elsewhere.
The right frame is not "China is better" — it is "for a specific set of patients, China is the available option."
7. Frequently Asked Questions
How many international patients seek treatment in China each year?
1.28 million visits in 2025, up 73.6% from three years earlier, with cross-border revenue above ¥80 billion in the first three quarters — per the NHC 2025 report.
Why do foreigners travel to China for cancer care?
Mostly access: therapies approved only in China (solid-tumor CAR-T, certain new immunotherapies), plus lower prices (blood-cancer CAR-T at ~⅓ of US prices) and faster care (48-hour workups, surgery in weeks).
How much does CAR-T cost in China?
A solid-tumor CAR-T infusion was reported at ¥990,000 (≈US$140,000); blood-cancer CAR-T is reported at about a third of US list prices. Always get a written quote.
Do hospitals speak English?
Yes, at leading centers. Jiahui handles eight languages and 20+ language medical records; Peking University International Hospital runs a dedicated international service line with pre-visit history collection.
Is treatment fast?
China is markedly faster: a full oncology workup with results and doctor discussion within 48 hours, and diagnosis-to-surgery in one to two weeks versus months in many Western systems.
Do I need to speak Chinese or have local insurance?
No. International wards are built for self-pay foreign patients and provide interpretation, logistics, and insurance-claim support. Most international patients pay out of pocket and claim reimbursement at home.
Get a Free Hospital Recommendation & Cost Estimate
Tell us your diagnosis and treatment history. We'll match you with 2-3 suitable international-care hospitals, confirm whether the therapy you need exists in China, and get written treatment and cost assessments. No obligation, 100% confidential, we reply within 24 hours.
- 📧 Email: contact@chinahospitalsguide.com
- 💬 WhatsApp: +86 157 6310 7083
- 📨 Telegram: @chinahospitalguide
- 💬 WeChat: chinahospitalguide
- 🌐 Start Free Case Review
Medical Disclaimer This article is general educational content only and does not constitute medical advice, a treatment recommendation, or an invitation to seek care. It cannot replace an in-person consultation with a licensed physician. Figures are drawn from a Caijing magazine investigation (September 2, 2026) and the National Health Commission's 2025 cross-border medical services report as cited therein; they describe populations and reported prices, not guarantees for any individual. Whether a treatment is suitable must be assessed by a qualified medical team. If you are ill, please follow the guidance of licensed clinicians at a proper medical institution.
Source disclosure This article is based on reporting by Caijing magazine / Caijing.com.cn, "¥990,000 a shot: foreigners come to China for cancer treatment" (September 2, 2026), including hospital interviews and government data cited therein. Patient names follow the public reporting. China Hospitals Guide is an independent hospital-matching platform and does not accept commissions from hospitals or guarantee referrals to any single institution.
Related Reading
- World's First International Patient Treated with Solid-Tumor CAR-T in China: The Satri-cel Case
- World's First CAR-T for Gastric Cancer: Satri-cel (CLDN18.2) in China
- Ivonescimab Cuts EGFR Lung Cancer Death Risk 24%: FDA Decision November 2026
- CAR-T Therapy Cost in China 2026
- CAR-T Therapy Hospitals in China 2026
- Cancer Treatment in China